Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
The employee options would add common shares if exercised, with vesting tied to continued service over four years.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annexon (Nasdaq: ANNX) granted options to purchase 1,270,000 common shares to six new non-executive employees on October 15, 2026.
The awards were approved on October 7 under the 2022 Employment Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a $3.60 exercise price, equal to the stock’s closing price on the grant date, and a ten-year term. They vest over four years: 25% on the first anniversary of the grant date and an additional 1/48th monthly thereafter, subject to continued service through each applicable vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 1,270,000 common shares at $3.60 per share create potential dilution if exercised.
Key Figures
- Employees receiving grants
- 6 employees
- New non-executive employees
- Options granted
- 1,270,000 shares
- Aggregate employee inducement awards
- Exercise price
- $3.60 per share
- Equal to the closing price on the grant date
- Option term
- 10 years
- Term of the options
- Vesting period
- 4 years
- 25% vests on the first anniversary; 1/48 monthly thereafter
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 7, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the six new non-executive employees received options to purchase 1,270,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What employee stock options did Annexon grant in October 2026?
Annexon granted six new non-executive employees options to purchase 1,270,000 common shares on October 15, 2026. The options have a ten-year term and an exercise price of $3.60 per share, equal to the stock’s closing price that day.
When do Annexon’s October 2026 employee stock options vest?
The options vest over four years, with 25% vesting on the first anniversary of the grant date and an additional 1/48th vesting monthly thereafter. Each employee must remain in service through the applicable vesting dates.